The Australia and New Zealand Transplant and Cellular Therapies Ltd (ANZTCT) is a society consisting of medical graduates and scientists involved in the clinical or laboratory management of patients undergoing blood or marrow stem cell transplantation or with an interest in the field of blood or marrow stem cell transplantation research.
Australia and New Zealand Transplant and Cellular Therapies Ltd is a registered charity with the Australian Charities and Non-for-profits Commission.
The goals of the Society are to
- to improve the outcome for Australians and New Zealanders of all ages undergoing transplantation of blood or marrow stem cells or other blood or marrow derived cells through innovation and improvements in clinical care
- to foster clinical and laboratory research in blood and marrow transplantation
- to track blood and marrow transplant activity and outcomes (via the Australasian Bone Marrow Transplant Recipient Registry)
- to monitor and facilitate the professional education and training of health workers involved in blood and marrow transplant activity
- to form collaborative links with other international organisations with similar objectives
- to raise funds in order to achieve its goals by soliciting funds, donations and moneys from members of the public, corporations, trusts and any other source approved by the Council
The affairs of the Society are managed by the ANZTCT Board of Directors, which consists of seven members including four office bearers (the president, the vice-president, the treasurer and the secretary) and three ordinary members including one representative from New Zealand and one paediatric transplant representative. Each member of the Board serves a three year term, and may be re-elected for a maximum of three consecutive terms.
Read the ANZTCT Constitution
Role of the ANZTCT Board of Directors
- to oversee activities of the Society in a manner that ensures the goals of the Society are effectively fulfilled
- to deliberate on membership issues including applications by new members
- to supervise the Australasian Bone Marrow Transplant Registry
- to deliberate on appropriate use of the Society’s funds in order to ensure that the Society’s goals are fulfilled
- to consider requests from ANZTCT members in relation to the functions of the Society
Board of Directors
A/Prof Nada Hamad
A/Prof Nada Hamad is a senior staff specialist bone marrow transplant, cellular therapies, clinical and laboratory haematologist at St Vincent’s hospital in Sydney, where she is also director of the haematology clinical trials unit. She is Chair of the ACI NSW BMT network and Chair of ALLG BMTCT working group. She also has a number of international leadership positions including membership of the WHO BMT quality taskforce. Dr Hamad studied Medicine at the University of Sydney and completed her Haematology training in Sydney. Prior to her career in medicine, she completed a Bachelor of Science and Master of Science in Forensics, working in this field for a short period of time. She completed two post-graduate fellowships in BMT and lymphoma at the Princess Margaret Cancer Centre in Toronto Canada through the University of Toronto. She has a strong interest in clinical trials and has a specialist certificate in Clinical Research (Oncology) from the University of Melbourne. Her clinical research interests are in malignant haematology and bone marrow transplantation. She is an intersectional feminist and a strong advocate for gender equity, diversity and inclusion in medicine. She is the deputy chair of the gender equity, diversity and inclusion in medicine committee at the University of NSW in Australia.
Dr Duncan Purtill
Dr Duncan Purtill is a laboratory and clinical haematologist and medical director of the Bone Marrow Transplant Laboratory at Fiona Stanley Hospital in Perth. He obtained his undergraduate degree from the University of Western Australia and completed most of his postgraduate training at Royal Perth Hospital. He has completed research and clinical fellowships in bone marrow transplantation, with a particular interest in cord blood transplantation, at Hôpital Saint Louis in Paris and at Memorial Sloan Kettering Cancer Centre in New York.
Dr Ashish Bajel
Dr Ashish Bajel is a clinical and BMT Haematologist, at the Royal Melbourne Hospital and Peter MacCallum Cancer Centre. He is the disease group lead for acute leukaemia and myelodysplastic syndrome. He oversees the umbilical cord blood transplant and haplo-identical bone marrow transplant programs at the VCCC. He is a member of disease group committees in the Australasian Leukaemia and Lymphoma Group (ALLG) and CIBMTR. He is committed to clinical and translational research aimed at developing new treatments for acute leukaemia and improving outcomes in allogeneic transplant.
Dr Jason Butler is a senior staff specialist at the Bone Marrow Transplant Unit, Royal Brisbane and Women’s Hospital. He has dual training in clinical and laboratory haematology. Dr Butler also completed a Masters in Medical Science (Clinical Epidemiology) to assist with development of investigator-initiator research studies. He is the chair of the EviQ haematology reference committee. His major clinical interests are in all aspects of malignant haematology, particularly in leukaemia, lymphoma, and myeloma, as well as autologous and allogeneic stem cell transplantation, including investigator roles on clinical studies in each of these fields. Dr Butler also undertakes other roles, including extensive educational support and clinical presentations for patients and health professionals, and advocacy roles as a board member for Lymphoma Australia.
Dr Richard Doocey
Dr Richard Doocey is a clinical and BMT haematologist and Director of the Auckland and Starship Children’s Hospital’s Stem Cell Transplant Program He was also Clinical Director of the Adult Haematology Service for 7 years until 2017. He completed training in Auckland, New Zealand and and subspecialty training in acute leukaemia, high grade lymphoma and bone marrow transplantation at Vancouver General Hospital and the British Columbia Cancer Agency. Richard also holds an appointment as the chair of the NZ Haematology Work Group interacting with the Ministry of Health.
Professor Tracey O’Brien
Professor Tracey O’Brien is the Director of the Kids Cancer Centre and the Head of the BMT program at the Sydney Children’s Hospital. She is a member of the CIBMTR advisory board, BMT NSW Executive Member and has served as past Vice President of the Australian and New Zealand Children’s Haematology and Oncology Group. She has expertise in treating childhood cancers with subspecialty training in stem cell transplant and is internationally recognised as a leader in umbilical cord blood transplant. In addition to her specialist medical training, Professor O’Brien holds a psychology degree, Masters in Law and an MBA bringing a unique skill set to lead cross functional research and clinical teams and translate innovation into health practice and policy. Her research interests include transplant outcomes, cellular therapies, health system research and bioethics.
Professor Ian Kerridge
General Council Member
Professor Ian Kerridge is Staff Specialist Haematologist, BMT physician and Collection Facilities Director at Royal North Shore Hospital, Sydney. He trained in medicine at the University of Newcastle, philosophy at the Universities of Sydney, Newcastle and Cambridge and BMT at the Royal Free Hospital in London. He is Co-Chair of the NSW BMT Network Long-term Follow-Up Working Group, Board Member of the NSW Stem Cell Network and was previously Chair of the NSW Cancer Institute’s EviQ HPT Reference Group (2006-2015). Ian is a Professor of Bioethics and Medicine at the University of Sydney, Chair of the RACP Ethics Committee, a member of the NSW Health Department’s Clinical Ethics Advisory Panel and was previously Chair of the ABMDR’s Research Ethics Committee. He is also Director of Praxis Australia – a Not-for-Profit initiative aimed at promoting and providing education in research. His current research interests include late effects of BMT, stem cell mobilization and multiple myeloma.